A brain hemorrhage is a sort of stroke. It is caused by an artery in the brain bursting and causes localized bleeding in the surrounding tissues. This bleeding is likely to kill brain cells. Brain hemorrhages are also called cerebral hemorrhages, intracranial hemorrhages, or intracerebral hemorrhages. They account for about 13% of strokes. There are more than a few risk factors that cause brain hemorrhages. The most common include head trauma, high blood pressure, aneurysms, and blood tumors.
A brain hemorrhage may exhibit a variety of symptoms, including sudden tingling, weakness, numbness, or the paralysis of the face, arms, or legs. This is mostly observed on just one side of the body. The number of brain hemorrhage cases is rising each year. According to the American Association of Neurological Surgeons, approximately 1.7 million cases of traumatic brain injury occur in the United States each year, and nearly 5.3 million people live with a disability due to their injury.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence